James Wooldridge

Checkmate Pharmaceuticals

SCHOLARLY PAPERS

1

DOWNLOADS

18

TOTAL CITATIONS

0

Scholarly Papers (1)

1.

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma

Number of pages: 95 Posted: 01 Jul 2024
University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Government of the United States of America - National Cancer Institute, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Johns Hopkins University, University of Pittsburgh Medical Center, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, University of Pittsburgh - Medical Center (UPMC), Government of the United States of America - National Cancer Institute, University of Pittsburgh, Government of the United States of America - National Cancer Institute, University of Pittsburgh, University of Pittsburgh, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, Government of the United States of America - National Cancer Institute, University of Pittsburgh, University of Pittsburgh Medical Center, University of Pittsburgh - Hillman Cancer Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, University of Pittsburgh Medical Center, Nanostring Technologies, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Checkmate Pharmaceuticals, Regeneron Pharmaceuticals Inc, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, University of Pittsburgh Medical Center, University of Pittsburgh - School of Medicine, University of Pittsburgh Medical Center, Johns Hopkins University, University of Pittsburgh, Government of the United States of America - National Cancer Institute, University of Pittsburgh Medical Center and Independent
Downloads 18 (1,191,448)

Abstract:

Loading...

melanoma, resectable, neoadjuvant, TLR, innate, PD-1, PD1, CTLA-4, CTLA4